Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is an electrolyte presented as a solution for extracorporeal use. It restores calcium balance during dialysis and other extracorporeal procedures in patients with renal impairment. GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Icalziss is used to address calcium deficits in the extracorporeal dialysis setting and related renal replacement therapies. - Dialysis‑associated hypocalcemia: restores ionized calcium levels during hemodialysis sessions. - Extracorporeal circuit calcium balance: maintains optimal calcium concentration in the dialysis circuit. - Renal replacement therapy: provides calcium supplementation for patients with impaired renal function undergoing continuous therapies.

Icalziss may be associated with a range of adverse reactions, most of which are related to calcium excess or infusion‑related irritation.

Common Side Effects: - Local irritation at the infusion site: mild redness or discomfort. - Transient hypercalcemia: temporary elevation of serum calcium. - Hypotension: occasional drop in blood pressure during infusion. - Nausea: mild gastrointestinal upset. - Muscle cramps: brief, self‑limiting spasms. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe hypercalcemia: marked elevation of calcium requiring medical intervention. - Cardiac arrhythmias: irregular heart rhythms linked to calcium imbalance. - Vascular calcification: deposition of calcium in blood vessels with prolonged exposure. - Acute pulmonary edema: fluid accumulation in lungs due to rapid calcium shifts. - Anaphylactic reaction: rare severe allergic response. - Metabolic alkalosis: disturbance of acid‑base balance.

When using Icalziss, clinicians should observe specific safety measures to minimise risks. - Monitor serum calcium levels: check before, during, and after infusion. - Assess cardiac function: observe ECG for arrhythmias, especially in patients with heart disease. - Adjust dose in renal impairment: consider residual kidney function and dialysis settings. - Avoid concurrent high calcium intake: limit dietary or supplemental calcium sources. - Use with caution in patients with vascular disease: risk of calcification. - Store below 25°C: keep in original container, protect from moisture and direct sunlight.

Calcium chloride can interact with several medications, altering their efficacy or safety profile.

Major Interactions (Avoid): - Bisphosphonates: concurrent use may precipitate severe hypocalcemia. - Vitamin D analogues (calcitriol, alfacalcidol): increase risk of hypercalcemia. - Loop diuretics (furosemide): may enhance calcium loss, requiring close monitoring.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure and renal function. - Beta‑blockers: observe for additive effects on heart rate. - Other electrolytes (magnesium, phosphate): maintain balanced levels to avoid precipitation. - Antacids containing aluminum or magnesium: may affect calcium absorption. - Quinolone antibiotics: calcium can reduce their bioavailability.